drugset / Trial / NCT06864143

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

NCT06864143

Phase 2 Completed 1320 enrolled ModernaTX, Inc.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.

Timeline

Start
2025-03-07
Primary completion
2025-10-13
Completion
2025-10-13

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1083 Messenger RNA (mRNA)